Globalization in the Pharmaceutical Industry, Part II

Tarabusi, Claudio Casadio; Vickery, Graham

doi:10.2190/b6vr-nnd7-46bl-py5g

Cited by 17 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pharmaceuticals can be divided into three categories: in-patent drugs, out-of-patent drugs, and generic and over-the-counter (OTC) drugs (Tarabusi and Vickery, 1995). This categorisation is in accordance with the typical business models of pharmaceutical companies associated with the regulatory regime.…”

Section: Scope Of the Pharmaceuticals Sectormentioning

confidence: 99%

See 1 more Smart Citation

Trade and Innovation: Pharmaceuticals

Kiriyama

2011

OECD Trade Policy Papers

View full text Add to dashboard Cite

Section: Scope Of the Pharmaceuticals Sectormentioning

confidence: 99%

“…Much attention has been paid to optimising the balance between providing adequate protection for new products and encouraging their widespread use (Tarabusi and Vickery, 1995). There have been a number of empirical studies on the economic impact of intellectual property, 126 and a subset of studies has focused specifically on pharmaceuticals.…”

mentioning

confidence: 99%

Trade and Innovation: Pharmaceuticals

Kiriyama

2011

OECD Trade Policy Papers

View full text Add to dashboard Cite

“…Companies such as Roche, Bristol-Myers Squibb, Abbott, Lilly, or Wyeth entirely closed down their infectious diseases divisions (Moran, 2005b: 9;Buse and Walt, 2000a: 552;Tarabusi andVickery, 1998a, 1998b). 2.…”

Section: Ghps As Response To Dual Market Failuresmentioning

confidence: 99%

Global public–private partnerships against neglected diseases: building governance structures for effective outcomes

Buckup

2008

HEPL

View full text Add to dashboard Cite

Focusing on the problem of pharmaceutical R&D for drugs and vaccines against neglected diseases in developing countries, this article argues that the effectiveness of global health partnerships potentially lies in their capacity to address the problem of dual market failures: on a first level they may tackle the poverty induced lack of effective demand for health products which impedes the creation of market-financed innovative products. On a second level, they may help overcoming hold-up problems and underinvestment induced by the complexity of neglected diseases R&D. Yet, organizing transactions within a partnership is not a panacea against these problems: a crucial determinant of success is proper ownership structures. They need to respond to (i) the degree to which the respective parties value the partnership outcome, (ii) the relative importance of the investment of the parties, and (iii) the nature of the partnership outcome. The argument developed in the analysis is built on an integrated framework combining insights from incomplete contracting theory and public goods economics. It is supported by a preliminary statistical analysis of 17 GHPs.

show abstract

“…Importantly, emerging markets such as Brazil, China, and India are rapidly becoming global players in the pharmaceutical industry, as both producers and consumers (Deutsch Bank Research, 2008). Table 18 Analysis by Taribusi and Vickery (1998) found that the pharmaceutical industry has been indeed undergoing major restructuring. This transition has been the result of a flurry of mergers and acquisitions as companies have sought to increase economies of scale (and with it cost savings, market access, and portfolios of products).…”

Section: Globalization and The Pharmaceutical Industrymentioning

confidence: 99%

Globalization and Health

Lee¹,

Yach²,

Kamradt‐Scott³

2003

147

View full text Add to dashboard Cite

Widespread consensus now exists that fundamental changes to human societies around the world are presently under way, a trend broadly referred to as globalization. Although this evolution is historically rooted in how all societies have formed and adapted over millennia, there is a sense that the changes of recent decades are more intense and accelerated. The resultant impacts of globalization potentially affect every individual and community.The changes arising from globalization can be understood to extend to the field of public health in three main ways. First, processes of global change are shaping the broad determinants of health. Along with individual lifestyle factors, globalization is influencing determinants of health such as employment, housing, education, water and sanitation, and agriculture and food production. Moreover, general socioeconomic, cultural, and environmental conditions are undergoing a transformation. Overall, globalization is restructuring human societies in diverse ways, and hence potentially influencing a broad range of factors that affect individual and population health.Second, a growing body of evidence indicates that health status and outcomes are being variably influenced by globalization. Many argue that globalization is giving rise to new patterns of health and disease linked to the consequent restructuring of human societies. These patterns include the spread of new and re-emerging diseases, as well as the reconfiguration of existing health challenges, including health inequalities within and across countries. In short, CH18-2 contemporary forms of globalization are producing winners and losers, and health outcomes are one reflection of this separation.Third, as a consequence of the factors mentioned previously, societies must adapt their collective responses to changing health determinants and outcomes. Within the broader context of global governance, and specifically global governance for health, globalization is influencing healthcare financing and service provision in a diverse range of countries, as well as the ways in which many products and services that affect health are regulated and marketed. The need to negotiate collective arrangements within and across countries, within the health sector and beyond, and across the public and private sectors has created new challenges.This chapter provides an overview of how globalization is affecting health determinants, health status and outcomes, and the regulatory environment for public health, including healthcare financing and service provision. These impacts can be collectively understood as the effects of the transition from international to global public health. The chapter begins by defining the often-used term "globalization," its key drivers, and the precise changes it is creating. This explication is followed by a discussion of the links between globalization and shifting patterns of infectious and chronic diseases. Finally, the effects on collective responses to global health challenges are explored through considera...

show abstract

Globalization in the Pharmaceutical Industry, Part II

Cited by 17 publications

References 0 publications

Trade and Innovation: Pharmaceuticals

Trade and Innovation: Pharmaceuticals

Global public–private partnerships against neglected diseases: building governance structures for effective outcomes

Globalization and Health

Contact Info

Product

Resources

About